1.Treatment with midazolam for sleep disturbance of terminally ill patients with cancer in general wards
Yuri Okuno ; Daisuke Kato ; Kumi Hasegawa ; Tadaaki Ito ; Mayumi Minowa ; Yoshiko Yamaura ; Kazuma Kishi ; Masahiro Hayashi
Palliative Care Research 2013;8(1):101-106
Background: In terminally ill patients with cancer, sleep disturbance makes worse their quality of life. Midazolam has not ever been used for the treatment of sleep disturbance in general wards of our hospital, used in palliative care unit of other hospital, however. Method: This is a retrospective study based on chart review. Twenty-eight patients who were treated with midazolam for sleep disturbance included in this study. We designed evaluation methods to strictly follow the actual chart descriptions. Efficacy was rated as good, fair, or poor. Safety was defined by the presence or absence of respiratory depression and hypotension. Results: The median administration periods and initial doses were 6 days (range, 1-151) and 5.0 mg/night (1.8-20.0), respectively. Fourteen patients showed good sleep a night after midazolam infusion, four and nine patients showed fair and poor sleep, respectively. No patient demonstrated a respiratory rate of less than 8/min and systolic blood pressure of <60 mmHg at any point during and after midazolam infusion. Conclusion: Intravenous midazolam appeared to be safe for sleep disturbance of terminally ill patients with cancer in general wards. A future improvement administration methods are necessary to treat for sleep disturbance more effectively as well as PCU.
2.The baseline recurrence risk of patients with intermediate-risk cervical cancer
Yutaka YONEOKA ; Mayumi Kobayashi KATO ; Yasuhito TANASE ; Masaya UNO ; Mitsuya ISHIKAWA ; Takashi MURAKAMI ; Tomoyasu KATO
Obstetrics & Gynecology Science 2021;64(2):226-233
Objective:
This study aimed to investigate the prognosis of patients with intermediate-risk cervical cancer and to evaluate the necessity of adjuvant therapy.
Methods:
We conducted a retrospective chart review of patients with stage IB–II cervical cancer who underwent type III radical hysterectomy with pelvic lymphadenectomy between 2008 and 2017. In our institution, radical hysterectomy is performed as an open surgery and not as a minimally invasive surgery, and adjuvant therapy is not administered to patients with intermediate-risk cervical cancer. The intermediate-risk group included patients with 2 or more of the following factors: tumor size >4 cm, stromal invasion >1/2, and lymphovascular stromal invasion. Intermediaterisk patients with squamous cell carcinoma were included in the I-SCC group, whereas those with endocervical adenocarcinoma, usual type, or adenosquamous carcinoma were included in the I-Adeno group.
Results:
There were 34 and 18 patients in the I-SCC and I-Adeno groups, respectively. The 5-year recurrence-free survival (RFS) and overall survival rates in the I-SCC group were 90.5% (95% confidence interval [CI], 85.3–95.7%) and 100% (95% CI, 100%), respectively, whereas those in the I-Adeno group were 54.9% (95% CI, 42.0–67.9%) and 76.1% (95% CI, 63.7–88.4%), respectively. Multivariate analysis revealed that endocervical adenocarcinoma, usual type, or adenosquamous carcinoma, and tumor size >4 cm had worse RFS.
Conclusion
The I-SCC group had good prognosis without adjuvant therapy; therefore, adjuvant therapy may be omitted in these patients. In contrast, the I-Adeno group had poor prognosis without adjuvant therapy; therefore, adjuvant therapy should be considered in their treatment.
3.The baseline recurrence risk of patients with intermediate-risk cervical cancer
Yutaka YONEOKA ; Mayumi Kobayashi KATO ; Yasuhito TANASE ; Masaya UNO ; Mitsuya ISHIKAWA ; Takashi MURAKAMI ; Tomoyasu KATO
Obstetrics & Gynecology Science 2021;64(2):226-233
Objective:
This study aimed to investigate the prognosis of patients with intermediate-risk cervical cancer and to evaluate the necessity of adjuvant therapy.
Methods:
We conducted a retrospective chart review of patients with stage IB–II cervical cancer who underwent type III radical hysterectomy with pelvic lymphadenectomy between 2008 and 2017. In our institution, radical hysterectomy is performed as an open surgery and not as a minimally invasive surgery, and adjuvant therapy is not administered to patients with intermediate-risk cervical cancer. The intermediate-risk group included patients with 2 or more of the following factors: tumor size >4 cm, stromal invasion >1/2, and lymphovascular stromal invasion. Intermediaterisk patients with squamous cell carcinoma were included in the I-SCC group, whereas those with endocervical adenocarcinoma, usual type, or adenosquamous carcinoma were included in the I-Adeno group.
Results:
There were 34 and 18 patients in the I-SCC and I-Adeno groups, respectively. The 5-year recurrence-free survival (RFS) and overall survival rates in the I-SCC group were 90.5% (95% confidence interval [CI], 85.3–95.7%) and 100% (95% CI, 100%), respectively, whereas those in the I-Adeno group were 54.9% (95% CI, 42.0–67.9%) and 76.1% (95% CI, 63.7–88.4%), respectively. Multivariate analysis revealed that endocervical adenocarcinoma, usual type, or adenosquamous carcinoma, and tumor size >4 cm had worse RFS.
Conclusion
The I-SCC group had good prognosis without adjuvant therapy; therefore, adjuvant therapy may be omitted in these patients. In contrast, the I-Adeno group had poor prognosis without adjuvant therapy; therefore, adjuvant therapy should be considered in their treatment.
4.Development and introduction of a regional cooperation clinical pathway for home palliative care
Koichiro Kobayashi ; Mayumi Murakami ; Tohru Tomiyama ; Nobuki Itakura ; Mariko Kato ; Izumi Nakaya ; Miwako Takeda ; Yuko Yokoyama ; Noriko Hirai ; Hiroyasu Kawakami
Palliative Care Research 2013;8(2):326-333
In order to promote regional cooperation in palliative care, we developed a regional cooperation clinical pathway for home palliative care that offers simple support and is easy to use. We then administered a questionnaire survey to 14 healthcare professionals with various specialties who were involved in the introduction of the pathway, and we revised the pathway on the basis of the survey results. The revised pathway was then tested in 13 patients who were discharged from 3 designated cancer care hospitals in Toyama City to home care, and another questionnaire survey was conducted afterwards in the same manner. The mean overall score on the questionnaire was 2 in seven, 3 in seven (on a scale of 0 to 3) at the time of introduction, whereas the score after trial use was 1 in one, 2 in four, 3 in five. We believe that more innovative approaches to the implementation of such pathways are required.
5.Support system probability using IT cloud for a palliative care team to support a home palliative care
Koichiro Kobayashi ; Mayumi Murakami ; Toru Tomiyama ; Mariko Kato ; Izumi Nakaya ; Miwako Takeda ; Yuko Yokoyama ; Noriko Hirai ; Hiroyasu Kawakami
Palliative Care Research 2013;8(2):371-375
Purpose and Methods: Aiming at the relief of suffering by the palliative care team and prompt information sharing between healthcare professionals with various specialties, We introduced new IT cloud system, carried out questionnaire survey and examined the usefulness to 11 persons of healthcare professionals. Five cases where the palliative care team was concerned during the hospitalize became a home palliative care to the tried half a year. Results: All the members were using the personal computer as an input device. Four persons were using the iPhone. Two persons had the experience inputted on the spot. Nine persons of the input time were 5 or less minutes. All the members were perusing at various places by various device. Urgently and vital mail was useful: 3 in six, 2 in three, 1 in one, 0 in one. Information content were suitable: 3 in nine, 2 in two. Cooperation were completed in the smooth: 3 in nine, 2 in two. Have you utilized EIR for the home palliative care?: 3 in nine, 2 in two. Conclution: To the support of information sharing and palliative care team by IT cloud system transduction, the useful probability was suggested in the home palliative care.
6.Experience with 10 Seminars and Workshops for Medical Education
Masayuki NIWA ; Yasuyuki SUZUKI ; Kazuhiko FUJISAKI ; Tomomi KATO ; Mayumi TANIMOTO ; Osamu MATSUO ; Naoki NAGO ; Ichiro YOSHIDA ; Yuzo TAKAHASHI
Medical Education 2005;36(2):89-96
We have organized the Seminar and Workshop for Medical Education (SWME) 10 times from 2000 through 2003. More than 1, 200 persons have participated, including teachers, physicians, students, and simulated patients. The themes of the SWME have included a problem-based learning tutorial system, medical interview skills, objective structured clinical examinations, medical ethics, advanced cardiac life support/basic life support, evidence-based medicine, coaching technology, medical English education, and crisis management education. Invited lecturers from throughout the country organized most of these workshops. Advantages of the SWME are two-fold:(1) improving the medical teaching skills of each participant and (2) scouting for good young lecturers. Workshop reports are published in our annual monographs and other materials. The present paper is a historical review of the SWME and also describes the nationwide scope of faculty development.
7.A pediatric case of anaphylactic shock induced by tipepidine hibenzate (Asverin)
Hirotake TAKAI ; Izumi KATO ; Kanako MITSUNAGA ; Mayumi HARA ; Takahiro KODAMA ; Masaki KANAZAWA ; Masaru TERAI
Asia Pacific Allergy 2018;8(4):e37-
Tipepidine hibenzate (Asverin) is commonly used as an antitussive drug for acute and chronic cough in various age groups and is generally safe and well-tolerated. However, we experienced a case of tipepidine hibenzate-induced anaphylactic shock in a 1-year-old boy. After ingesting cold medication including tipepidine hibenzate, the patient presented with generalized erythema and urticaria, swollen face, coughing, wheezing and vomiting, together with hypotension and a decreased level of consciousness. To identify the culprit drug, we performed skin prick tests (SPTs) and oral drug provocation tests (DPTs). SPTs revealed a negative reaction for all drugs, but DPTs caused a positive reaction only for a full therapeutic dose of tipepidine hibenzate. Physicians need to consider tipepidine hibezate as a culprit drug when anaphylaxis occurs after taking anticough or common cold medication.
Anaphylaxis
;
Child
;
Common Cold
;
Consciousness
;
Cough
;
Drug Hypersensitivity
;
Erythema
;
Humans
;
Hypotension
;
Male
;
Respiratory Sounds
;
Skin
;
Urticaria
;
Vomiting
8.Is three-piece maxillary segmentation surgery a stable procedure?
Renata Mayumi KATO ; João Roberto GONÇALVES ; Jaqueline IGNÁCIO ; Larry WOLFORD ; Patricia Bicalho DE MELLO ; Julianna PARIZOTTO ; Jonas BIANCHI
The Korean Journal of Orthodontics 2024;54(2):128-135
Objective:
The number of three-piece maxillary osteotomies has increased over the years; however, the literature remains controversial. The objective of this study was to evaluate the skeletal stability of this surgical modality compared with that of one-piece maxillary osteotomy.
Methods:
This retrospective cohort study included 39 individuals who underwent Le Fort I maxillary osteotomies and were divided into two groups: group 1 (three pieces, n = 22) and group 2 (one piece, n = 17). Three cone-beam computed tomography scans from each patient (T1, pre-surgical; T2, post-surgical; and T3, follow-up) were used to evaluate the three-dimensional skeletal changes.
Results:
The differences within groups were statistically significant only for group 1 in terms of surgical changes (T2-T1) with a mean difference in the canine region of 3.09 mm and the posterior region of 3.08 mm. No significant differences in surgical stability were identified between or within the groups. The mean values of the differences between groups were 0.05 mm (posterior region) and –0.39 mm (canine region).
Conclusions
Our findings suggest that one- and three-piece maxillary osteotomies result in similar post-surgical skeletal stability.
9.Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer
Naoya MURAKAMI ; Miho WATANABE ; Takashi UNO ; Shuhei SEKII ; Kayoko TSUJINO ; Takahiro KASAMATSU ; Yumiko MACHITORI ; Tomomi AOSHIKA ; Shingo KATO ; Hisako HIROWATARI ; Yuko KANEYASU ; Tomio NAKAGAWA ; Hitoshi IKUSHIMA ; Ken ANDO ; Masumi MURATA ; Ken YOSHIDA ; Hiroto YOSHIOKA ; Kazutoshi MURATA ; Tatsuya OHNO ; Noriyuki OKONOGI ; Anneyuko I. SAITO ; Mayumi ICHIKAWA ; Takahito OKUDA ; Keisuke TSUCHIDA ; Hideyuki SAKURAI ; Ryoichi YOSHIMURA ; Yasuo YOSHIOKA ; Atsunori YOROZU ; Naonobu KUNITAKE ; Hiroyuki OKAMOTO ; Koji INABA ; Tomoyasu KATO ; Hiroshi IGAKI ; Jun ITAMI
Journal of Gynecologic Oncology 2023;34(3):e24-
Objective:
The purposes of this trial were to demonstrate the feasibility and effectiveness of the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced cervical cancer patients in the phase I/II prospective clinical trial.
Methods:
Patients with FIGO stage IB2-IVA uterine cervical cancer pretreatment width of which was ≥5 cm measured by magnetic resonance imaging were eligible for this clinical trial. The protocol therapy included 30–30.6 Gy in 15–17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP, followed by 24 Gy in 4 fractions of HBT and pelvic radiotherapy with a central shield up to 50–50.4 Gy in 25–28 fractions. The primary endpoint of phase II part was 2-year pelvic progression-free survival (PPFS) rate higher than historical control of 64%.
Results:
Between October 2015 and October 2019, 73 patients were enrolled in the initial registration and 52 patients proceeded to the secondary registration. With the median follow-up period of 37.3 months (range, 13.9–52.9 months), the 2- PPFS was 80.7% (90% confidence interval [CI]=69.7%–88%). Because the lower range of 90% CI of 2-year PPFS was 69.7%, which was higher than the historical control ICBT data of 64%, therefore, the primary endpoint of this study was met.
Conclusion
The effectiveness of HBT were demonstrated by a prospective clinical study. Because the dose goal determined in the protocol was lower than 85 Gy, there is room in improvement for local control. A higher dose might have been needed for tumors with poor responses.
10.Sensor monitoring to determine daily physical functioning among post-stroke older people in a home setting: Pilot study
Andi Masyitha Irwan ; Mayumi Kato ; Yudi Hardianto ; Syahrul Syahrul ; Ilham Bakri ; Miho Shogenji ; Elly Lilianty Sjattar
Philippine Journal of Nursing 2024;94(2):25-35
Background:
Almost half of the population of stroke patient were aged 65 and older. Elderly patients who had a stroke were at risk of loneliness and isolation due to their frailty, inactivity, and difficulty moving.
Objective:
This study determined the daily physical functioning among post-stroke older people by sensor monitoring and matching data with the Functional Independence Measure (FIM).
Methods:
Sixteen home-dwelling post-stroke older people participated in this descriptive cross-sectional study. Daily functioning was measured using Physical Activity Monitor AM300 sensor devices and FIM. In addition, data on stroke history, fall history activities, blood pressure measurements, walking speed, leg muscle strength, grip strength, balance, pain, fall risk, fear of falling, selfefficacy, and nutritional intake were collected as demographic characteristics of the participants.
Results:
Most participants spent their time on at-home activities and very little time on sports activities. These findings were matched with FIM results where only one-fourth of participants had complete independence in locomotion walking, and no participants had complete independence in locomotion stairs.
Conclusions
Sensor monitoring and FIM could be combined to determine daily functioning and the type of rehabilitation needed by post-stroke patients.
Functional Status